Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Ervogastat (PF-06865571) With or Without Clesacostat (PF-05221304) in NASH With Fibrosis Stage 2 or 3
jRCT2080225223Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Ervogastat monotherapy, Ervogastat + clesacostat and Placebo (3 arms). Primary endpoint: Pre-defined primary histologic endpoint. Started Jun 2020; status: completed.
02
Drugs
ervogastatclesacostat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2080225223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225223.